Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GS-1423 |
Synonyms | |
Therapy Description |
GS-1423 is an aglycosylated bispecific antibody that targets CD73 and TGFbeta, potentially resulting in antitumor activity (PMID: 36746510). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GS-1423 | AGEN1423|AGEN 1423|AGEN-1423|GS1423|GS 1423|Dalutrafusp alfa | CD73 Antibody 12 TGFB (Pan) Antibody 5 | GS-1423 is an aglycosylated bispecific antibody that targets CD73 and TGFbeta, potentially resulting in antitumor activity (PMID: 36746510). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03954704 | Phase I | Fluorouracil + GS-1423 + Leucovorin + Oxaliplatin GS-1423 | Study of GS-1423 in Participants With Advanced Solid Tumors | Terminated | USA | 0 |